FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/10/2026
Back to search
Official data from USPTO
C CARSGEN THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
06/11/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
05/07/2024
Registration date
03/10/2026
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/10/2026
Last transaction
06/11/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
CN
Examiner
CROWDER-SCHAEFER, ANDREW W
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CARSGEN THERAPEUTICS CO., LTD.
Representatives
Adam Bell Bell IP Law
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Diagnostic preparations for medical purposes; biological tissue cultures for medical purposes; stem cells for medical purposes; liquid medicines for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; injectable medicinal solutions in the nature of pharmaceutical preparations for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; pharmaceutical preparations for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; drugs for medical purposes in the nature of pharmaceutical preparations for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases; vaccines; biological preparations for the treatment of tumorscancerautoimmune diseases or disordersinflammatory diseasescardiovascular diseasesdigestive system diseasesdiabetes mellitusendocrine and metabolic diseaseschronic respiratory diseasesnervous system diseasesbone and joint diseasesmental and psychological diseaseschronic kidney diseaseseye and ear diseasescongenital genetic cardiovascular and neurological diseasesinfectious diseasesimmune system related diseases and disordersblood diseases for medical purposes; blood preparationsblood for medical purposes
Publications
History of USPTO decisions and trademark events.
28 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/10/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
03/10/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/20/2026
PUBO
PUBLISHED FOR OPPOSITION
01/20/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/14/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/22/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/17/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/17/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/17/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
12/14/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/14/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/14/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/14/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/14/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/05/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/19/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/19/2025
RFNT
REFUSAL PROCESSED BY IB
07/26/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/04/2025
RFRR
REFUSAL PROCESSED BY MPU
07/04/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/22/2025
CNRT
NON-FINAL ACTION WRITTEN
04/21/2025
DOCK
ASSIGNED TO EXAMINER
04/21/2025
MAFR
APPLICATION FILING RECEIPT MAILED
04/18/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/18/2025
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
06/28/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/20/2024
Continuous trademark protection
Get notified about every new filing that threatens C CARSGEN THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.